Cellosaurus logo
expasy logo

Cellosaurus Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical] (CVCL_E6DN)

[Text version]
Cell line name Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical]
Synonyms Ba/F3 EGFR-V769insASV
Accession CVCL_E6DN
Resource Identification Initiative To cite this cell line use: Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical] (RRID:CVCL_E6DN)
Comments Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3236; EGFR (Note=With p.Val769insAlaSerVal (c.2308_2309insCCAGCGTGG)).
Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Cell type: Pro-B cell; CL=CL_0000826.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: C3H.
Hierarchy Parent: CVCL_0161 (Ba/F3)
Category Factor-dependent cell line
Publications

PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206
Hasako S., Terasaka M., Abe N., Uno T., Ohsawa H., Hashimoto A., Fujita R., Tanaka K., Okayama T., Wadhwa R., Miyadera K., Aoyagi Y., Yonekura K., Matsuo K.
TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations.
Mol. Cancer Ther. 17:1648-1658(2018)

PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M., Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A., Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B., Kobayashi S.S.
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019)

Entry history
Entry creation10-Apr-2025
Last entry update10-Apr-2025
Version number1